Theralase Technologies (TLT) Q1 2025 earnings summary

Executive summary

• Enrollment in the pivotal bladder cancer study is expected to complete by summer 2025, enabling a new drug application submission to Health Canada and the FDA by Q4 2026, with potential marketing approval in early 2027 if priority review is granted.

• The company is expanding its pipeline to nine additional oncology and virology indications, with GLP toxicology studies expected to finish by end of 2025 and adaptive phase 1/2 clinical studies to begin in Q1 2026.

• Strategic initiatives include a potential U.S. uplist, concurrent U.S. institutional financing, and separation of drug and device division reporting and funding.

• Operational focus remains on advancing clinical programs, securing additional financing, and seeking commercialization partners for RuvidarⓇ.

• FDA acknowledged impressive interim data but advised completion of Study II before NDA submission.

Financial highlights

• Q1 2025 revenue was CAD 91,000 (or $91,190), down 48% year-over-year from CAD 175,000, reflecting focus on clinical study investment.

• Gross margin was CAD 13,000 (or $13,294), 15% of revenue, impacted by reduced sales and fixed overhead.

• Operating expenses: selling CAD 68,000 (flat), administrative CAD 555,000 (up 9%), R&D CAD 878,000 (up 16%).

• Net loss for the quarter was CAD 1.47 million (or $1,471,250), including CAD 256,000 in non-cash charges.

• Cost of sales represented 85% of revenue, up from prior year.

Outlook and guidance

• Study II enrollment expected to complete by summer 2025, with final data on 90 patients by September 2026.

• NDA submission to Health Canada and FDA planned for Q4 2026, with regulatory decisions anticipated in 2027.

• Estimated CAD 8–10 million required to complete study two, follow-up, data lock, and regulatory submissions over the next 18 months.

• Exploring U.S. institutional raise, public listing, and commercialization partnerships to broaden investor base and fund pipeline expansion.